Altimmune, Inc. (ALT) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reveals strong financial health with increased cash reserves and reduced net loss. Product development is progressing, with promising trials and strategic FDA interactions. The Q&A highlights optimism about innovative approaches, like AI-based biopsy readings, and differentiation in competitive markets. Despite some unclear responses, the overall sentiment is positive due to financial stability, strategic developments, and potential market differentiation.
Key Financial Performance
Total Cash $211 million as of September 30, 2025, representing an increase of 60% over the cash position at the start of the year. The increase was due to raising $127 million through the first 9 months of the year and amending the Hercules debt agreement to increase the facility size to $125 million.
R&D Expenses $15 million for the 3 months ended September 30, 2025, compared to $19.8 million in the same period of 2024. The decrease was related to the timing of CRO development costs year-over-year. The Q3 2025 spend included $9.2 million of direct costs related to pemvidutide development.
G&A Expenses $5.9 million for the quarter ended September 30, 2025, compared to $5 million in the same period of 2024. The increase was driven by professional fees and noncash stock-based compensation.
Net Loss $19 million or $0.21 per share for the third quarter of 2025, compared to $22.8 million or $0.32 per share in the third quarter of 2024. The reduction in net loss was due to lower R&D expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Pemvidutide: The foundation of Altimmune's pipeline, targeting serious liver diseases like MASH, AUD, and ALD. Demonstrated rapid efficacy in MASH resolution and antifibrotic activity in 24-week IMPACT trial data. Preparing for Phase III trials and awaiting 48-week IMPACT data readout.
Market research in Europe: Feedback from healthcare professionals and payers indicates high likelihood of prescribing pemvidutide for MASH. Positive reimbursement outlook across the EU with broad coverage expected.
Financial position: Total cash of $211 million as of September 30, 2025, a 60% increase from the start of the year. Raised $127 million in the first 9 months of 2025 and amended debt agreements to increase financial flexibility.
Executive team expansion: New appointments include Dr. Christophe Arbet-Engels as Chief Medical Officer, Linda Richardson as Chief Commercial Officer, and Robin Abrahams as Chief Legal Officer.
Regulatory alignment: Preparing for an end of Phase II meeting with the FDA to discuss Phase III trial design for pemvidutide, including the potential use of noninvasive tests (NITs) as approvable endpoints.
Pipeline expansion: Initiated Phase II trials for AUD and ALD, with rapid enrollment in the RECLAIM trial for AUD and ongoing enrollment in the RESTORE trial for ALD.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Uncertainty: The company is preparing for a Phase III trial and is relying on regulatory agencies potentially aligning with clinical practices, such as using noninvasive tests (NITs) as measures of efficacy. However, this regulatory alignment is not guaranteed, posing a risk to trial design and approval timelines.
Financial Risks: Although the company has raised significant capital and strengthened its balance sheet, it is still reliant on external funding mechanisms, such as a $400 million shelf registration and a $200 million ATM facility. This reliance on external funding could pose risks if market conditions change or if additional capital is not raised as planned.
Clinical Trial Risks: The success of the company's pipeline, particularly pemvidutide, hinges on the outcomes of ongoing and future clinical trials. Any delays, failures, or adverse results in these trials could significantly impact the company's strategic objectives and financial performance.
Market Adoption Challenges: While initial market research indicates strong interest in pemvidutide, actual market adoption will depend on factors such as payer reimbursement, competition, and the ability to demonstrate clear differentiation from existing therapies.
Operational Risks: The company is undergoing significant operational changes, including the addition of new executive team members. While these changes aim to strengthen the organization, they also introduce risks related to team integration and execution of strategic plans.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
48-week IMPACT data readout: Expected to be shared before the end of the year, focusing on the potential of longer treatment duration on NIT measurement, further weight loss, and continued efficacy in MASH resolution.
Phase III clinical development for pemvidutide: Preparations are underway for Phase III trials, with a scheduled end of Phase II meeting with the FDA before year-end to review the proposed program. The trial may include flexibility in using NITs and AI reads as approvable endpoints.
RECLAIM Phase II trial for AUD: Enrollment completed ahead of schedule, with results expected next year. This trial evaluates pemvidutide's potential as a therapy for alcohol use disorder.
RESTORE Phase II trial for ALD: Enrollment began in Q3, focusing on pemvidutide's potential for alcohol-associated liver disease, a condition with no approved therapies.
Regulatory considerations for MASH: Regulatory agencies are considering allowing the use of NIT data as a measure of efficacy in MASH clinical trials, aligning with clinical practice. This could benefit pemvidutide given its strong NIT data.
Commercialization plans for pemvidutide: Market research in Europe indicates high physician interest in prescribing pemvidutide for MASH, with positive reimbursement outlooks from payers. Commercial considerations are being integrated into the Phase III program to highlight differentiators.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How much of the 48-week data from the Phase II IMPACT MASH will inform the conversation with the FDA and the Phase III design?
A:The 48-week data will not be part of the end of Phase II meeting with the FDA, as the meeting was requested based on the 24-week data. The FDA has granted the meeting based on the strength of the 24-week data. The 48-week data will be submitted when available and will help confirm the findings of the 24-week data.
Q:What is the current thinking about the Phase III design based on the 48-week data?
A:The Phase III design will be flexible to adapt to regulatory changes, including potential shifts from biopsy readings to NITs or AI-based biopsy endpoints. The goal is to incorporate any changes that occur over the next months or year.
Q:What are the probabilities of using NITs or AI-based histological reading in Phase III studies?
A:There is increasing interest in NITs, and discussions are ongoing, including at the upcoming AASLD meeting. AI-based biopsy reading offers advantages such as reduced variability and comprehensive evaluations. The EMA has already approved AI-based approaches for biopsies.
Q:What is the primary endpoint of the RECLAIM trial?
A:The primary endpoint is the number of heavy drinking days per week, with changes from baseline being measured.
Q:What magnitude of change at 48 weeks would reinforce confidence in fibrosis improvement as a key Phase III endpoint?
A:Continued maintenance and additional improvement in NITs at 48 weeks would reinforce confidence. The 24-week data already showed strong antifibrotic activity, and further improvements are expected.
Q:What level of incremental weight loss or lean mass preservation would support differentiation of pemvidutide?
A:Continued weight loss and lean mass preservation, as seen in the MOMENTUM trial, would support differentiation. Pemvidutide showed a lean loss ratio of about 22% over 48 weeks, which is closer to natural weight loss compared to other agents.
Q:What are the distinct opportunities in alcoholic use disorder (AUD) and alcoholic liver disease (ALD)?
A:AUD and ALD are interconnected, with AUD often leading to ALD. The dual mechanism of action of pemvidutide addresses both conditions, offering potential success in both areas.
Q:How does the company plan to position pemvidutide in the MASH market given competition from other drugs like semaglutide and Retatrutide?
A:The company emphasizes pemvidutide's dual mechanism of action, early onset of activity, and comprehensive benefits in one molecule. It aims to differentiate based on early activity, tolerability, and the ability to monitor improvements without long waiting periods.
Q:What activities are planned for the upcoming AASLD meeting to raise awareness of pemvidutide?
A:The company plans to engage with KOLs, patient advocacy groups, and clinical investigators. It will also present two late-breaking presentations (one oral and one poster) and host a reception to discuss the drug's potential.
Q:What are the next steps for the oral formulation of pemvidutide?
A:The oral formulation program is progressing, with plans for an IND and clinical trial. The oral form will act like the injectable once in the bloodstream, offering the same benefits and tolerability.
Q:Review of Unclear Management Responses
A:Management avoided directly answering questions about the specific magnitude of change expected at 48 weeks to reinforce confidence in fibrosis improvement. They also did not provide clear details on the operational implementation of NIT tracking in Phase III or the exact timeline for the oral formulation program.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AUD ALD
Arbet Engels
Chief Commercial
Christophe Arbet
Commercial Officer
Dr Christophe
Dr Garg
Engels Chief
GLP agonism
II meeting
III MASH
MASH AUD
MASH therapy
NIT
Officer Richardson
Phase II
Phase III
Richardson Chief
alcohol
amendment
balance sheet
enrollment RECLAIM
face
feedback
glucagon GLP
interest
liver disease
mechanism action
need
payer
pemvidutide therapy
potential pemvidutide
practice
sarcopenia
week readout
ALT Transcript
Altimmune, Inc. (ALT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-10
Altimmune, Inc. (ALT) Q1 2026 Earnings Call Transcript
Unknown5-14
The earnings call summary provides mixed signals: a 12% revenue increase and reduced net loss are positive, but increased G&A expenses and a lack of strategic updates or shareholder returns are concerning. The Q&A section offers no additional insights. Overall, the financial improvements balance the uncertainties, resulting in a neutral sentiment.
Altimmune, Inc. (ALT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-12
Altimmune, Inc. (ALT) Q4 2025 Earnings Call Transcript
Positive3-5
The company's strategic plan highlights strong clinical progress, particularly with pemvidutide's development in MASH and AUD, and positive market research in Europe. The Q&A session revealed no major negative concerns, and the company has a solid financial runway. The FDA's cautious stance on NITs as endpoints is a minor setback but does not overshadow the overall positive sentiment. The absence of market cap data limits the prediction's precision, but the strategic advancements suggest a positive stock price movement.
ALT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
